logo
  

Roche Receives FDA Emergency Use Authorization For Its Test To Detect Monkeypox Virus

The U.S. Food and Drug Administration granted Emergency Use Authorization for cobas MPXV for use on the cobas 6800/8800 Systems. The test is a real time PCR test for the qualitative detection of DNA from monkeypox virus or MPXV in lesion swabs collected from individuals suspected of monkeypox infection by their healthcare provider, Roche (RHHBY) said in a statement on Wednesday.

cobas MPXV targets two different regions of the MPXV genome, which are both less prone to mutations than other parts of the genome. The dual-target approach ensures that cobas MPXV will continue to detect the virus even if a mutation occurs in one of the target regions.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT